Observational studyPLoS neglected tropical diseases2018
Beneficial effects of benznidazole in Chagas disease: NIH SaMi-Trop cohort study.
Observational study in PLoS neglected tropical diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02646943 (Longitudinal Study of Patients With Chronic Chagas Cardiomyopathy in Brazil), which is not on this map. Cited by 62 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Longitudinal Study of Patients With Chronic Chagas Cardiomyopathy in Brazil (SaMi_Trop Project)
Who cites it
62 citing papers in PubMed, 2 syntheses or guidelines pooled it, 92 citations in OpenAlex.
- SBC Guideline on the Diagnosis and Treatment of Patients with Cardiomyopathy of Chagas Disease - 2023.Arquivos brasileiros de cardiologia · 2023Guideline
- Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection).The Cochrane database of systematic reviews · 2020Pooled it
- Detection of Trypanosoma cruzi by PCR in adults with chronic Chagas disease treated with nifurtimox.PloS one · 2019Trial
- Vaccines against chronicExpert review of vaccines · 2026Review
- Effectiveness of benznidazole in the treatment of Chagas disease in children and adults: a long-term retrospective cohort study.Antimicrobial agents and chemotherapy · 2026Article
- Factors associated with major electrocardiographic abnormalities in chagas disease patients: SaMi-trop cohort.International journal of cardiology. Heart & vasculature · 2026Article
- Advances and challenges in the search for new treatments for Chagas disease.Memorias do Instituto Oswaldo Cruz · 2026Review
- Clinical Progression of Cardiac ChronicPathogens (Basel, Switzerland) · 2025Article
- Long-term outcomes of benznidazole treatment in chronic Chagas disease: A 27-year cohort study of parasitological cure and death in the Jequitinhonha Valley, Brazil.PLoS neglected tropical diseases · 2025Article
- Sex Differences in Chagas Cardiomyopathy: a Comprehensive Review.Current heart failure reports · 2025Review
- Genetic diversity of Trypanosoma cruzi in individuals with chronic Chagas disease in the Northern Minas Gerais and Vale do Jequitinhonha regions, Minas Gerais, Brazil.PLoS neglected tropical diseases · 2025Article
- Article
- Chagas Disease in Northern California: Observed Prevalence, Clinical Characteristics, and Outcomes Within an Integrated Health Care Delivery System.The Permanente journal · 2025Article
- Bridging the gap in Chagas disease management: a mixed-methods study using an implementation science approach within the Brazilian primary health care system-'Implementa-Chagas/SaMi-Trop project'.Lancet regional health. Americas · 2025Article
- Antitrypanosomal therapy for Chagas disease: A single center experience with adverse drug reactions and strategies for enhancing treatment completion.PLoS neglected tropical diseases · 2025Article
- Chagas Disease in a Non-Endemic Setting: Clinical Profile, Treatment Outcomes, and Predictors of Cure in a 15-Year Cohort Study.Tropical medicine and infectious disease · 2025Article
- Cardiac and Digestive Forms of Chagas Disease: An Update on Pathogenesis, Genetics, and Therapeutic Targets.Mediators of inflammation · 2025Review
- Evaluation of strategies for the diagnosis of Chagas disease in an endemic area: SaMi-Trop study.Revista do Instituto de Medicina Tropical de Sao Paulo · 2025Article
- Article
- Impact of antiparasitic therapy on cardiovascular outcomes in chronic Chagas disease. A systematic review and meta-analysis.EClinicalMedicine · 2025Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 8 institutions in 2 countries.
Funding
Abstract
backgroundThe effectiveness of anti-parasite treatment with benznidazole in the chronic Chagas disease (ChD) remains uncertain. We evaluated, using data from the NIH-sponsored SaMi-Trop prospective cohort study, if previous treatment with benznidazole is associated with lower mortality, less advanced cardiac disease and lower parasitemia in patients with chronic ChD.
methodsThe study enrolled 1,959 ChD patients and abnormal electrocardiogram (ECG) from in 21 remote towns in Brazil. A total of 1,813 patients were evaluated at baseline and after two years of follow-up. Those who received at least one course of benznidazole were classified as treated group (TrG = 493) and those who were never treated as control group (CG = 1,320). The primary outcome was death after two-year follow-up; the secondary outcomes were presence at the baseline of major ChD-associated ECG abnormalities, NT-ProBNP levels suggestive of heart failure, and PCR positivity.
resultsMortality after two years was 6.3%; it was lower in the TrG (2.8%) than the CG (7.6%); adjusted OR: 0.37 (95%CI: 0.21;0.63). The ECG abnormalities typical for ChD and high age-adjusted NT-ProBNP levels suggestive of heart failure were lower in the TrG than the CG, OR: 0.35 [CI: 0.23;0.53]. The TrG had significantly lower rates of PCR positivity, OR: 0.35 [CI: 0.27;0.45].
conclusionPatients previously treated with benznidazole had significantly reduced parasitemia, a lower prevalence of markers of severe cardiomyopathy, and lower mortality after two years of follow-up. If used in the early phases, benznidazole treatment may improve clinical and parasitological outcomes in patients with chronic ChD.
trial registrationClinicalTrials.gov, Trial registration: NCT02646943.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.